Factors affecting the treatment of multiple colorectal adenomas

Emanuele D L Urso1, Riccardo Nascimbeni, Salvatore Pucciarelli

  • 1Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche, Azienda Ospedaliera University of Padova, Padova, Italy. edl.urso@unipd.it

Surgical Endoscopy
|July 10, 2012
PubMed
Abstract

Insights

The number of colorectal polyps, not genetic mutations, influences treatment intensity for patients with multiple colorectal adenomas (MCRA). Over 25 polyps often indicates a need for surgical intervention rather than endoscopic removal.

Area of Science:

  • Gastroenterology
  • Colorectal Surgery
  • Oncology

Background:

  • Multiple colorectal adenomas (MCRA) lack established treatment guidelines.
  • This study investigates factors influencing treatment decisions for MCRA.

Purpose of the Study:

  • To identify clinical and molecular factors associated with different treatment modalities for MCRA.
  • To provide evidence-based insights for managing patients with numerous colorectal polyps.

Main Methods:

  • Retrospective analysis of 80 MCRA patients (2003-2011).
  • Collected clinical, molecular (APC, MutYH genes), and family history data.
  • Classified treatments into endoscopic polypectomy, segmental resection, and total colectomy.
  • Utilized logistic regression and ROC curve analysis.

Main Results:

  • 80 patients (median 33 polyps) included; 43% had colorectal cancer (CRC).
  • Mutations found in 24% (MutYH) and 5% (APC).
  • Number of polyps and CRC presence correlated with more intensive treatment.
  • For non-CRC patients, polyp count was the primary factor for treatment severity.
  • 25 polyps best distinguished between endoscopic and surgical treatment.

Conclusions:

  • Most MCRA patients require surgical intervention.
  • Polyp number, not mutations, dictates treatment intensity in non-CRC patients.
  • More than 25 polyps predict a higher likelihood of surgical resection.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD: